Article citationsMore>>

Wang, X. and Wei. W. (2022) HR Positive/HER2 Negative Breast Cancer CDK4/6 Inhibitor Combined with Endocrine Therapy—Interpretation of the Chinese Society of Clinical Oncology (CSCO) Guidelines for Diagnosis and Treatment of Breast Cancer (2022 Edition). Zhejiang Medical, 44, 2595-2599.

has been cited by the following article:

• TITLE: Research Progress of Breast Cancer Stem Cell Stemness and Breast Cancer Recurrence

  AUTHORS: Huifang Zeng, Guanming Lu

  KEYWORDS: Breast Cancer Stem Cells, Stemness, Recurrence, Tumour Microenvironment, Drug Resistance

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.12 No.8, August 23, 2024

  ABSTRACT: Currently, breast cancer is the most common malignant tumour in Chinese women with a high incidence rate, and recurrence and metastasis are the main reasons affecting survival. Breast Cancer Stem Cells (BCSCs) are stem cells capable of continuous regeneration in vivo with strong self-renewal ability and multidirectional differentiation potential, which are highly tumourigenic and insensitive to radiotherapy and chemotherapy, and are highly susceptible to breast cancer recurrence. Therefore, exploring the stemness of BCSCs and their mechanism associated with recurrence is important for developing new therapeutic strategies, improving therapeutic efficacy, and improving patient prognosis.